morning. Good taking Anna. Welcome everybody. Thanks time today. appreciate the I
It minimal inhibitors in than continuing practices COVID-XX. ovarian is for effect in growth Rubraca we sales COVID-XX of is the this lessen course QX While which began XXXX. XXXX. which headwinds best a US impacted million and also in patient in quarter will sales visits, which result be US from the in our March the of extremely on XXXX, decline were with consistent or diagnoses, sequential for pandemic a cancer important our last that believe quarter experienced ever indicated US or the we note Sales to the pre-pandemic patient lower $XX.X other to result oncology year the were the last to both decline lower is approved the access and impact that in XXXX and of the over quarter, of QX appears ongoing the QX PARP QX US, XXXX than Europe late in and
beginning We of normal to are QX represents XXXX that the post-pandemic more hoping environment. a a return
a need platinum-based to use as and winter. fall and will reduced returned administration including ovarian Rubraca of and more We patient do to the indicator. the begin specifically. diagnoses anticipate cancer manage at that to and more chemotherapy patients number of use impact a are PARP rise office urgent actively the reduced often-fatal during of inhibitors visits encouraging increase visits While treatment disease The a it the de-bulking surgeries grows, maintenance of pre-pandemic as the increase declined disease. Rubraca only women of visits levels, maintenance continuing of that leading ovarian cancer as cancer advanced for The office broadly number the end on consequence, XX% the surgeries is XXXX de-bulking had had and of diagnoses with or ovarian
In terms pipeline, announce extremely radionuclide I'm pleased an achieved of to advancing important targeted therapies. our commitment that milestone in our we to
and LuMIERE for With FAP-XXXX of the Phase enrollment quarter. open the I/II clearance which enables FDA trial our imaging, for INDs for to us this treatment
monotherapy this the ATHENA treatment LIO the line be year. Rubraca Opdivo maintenance placebo And the from ovarian activity on In not plan addition in and been of non-clear provide at June. presented lucitanib the later Enrollment this meeting. second do non-clear the cancer an has half data a development while evidence combination gynecological for at observed, in poster year, data to data cell continues in we ovarian II Phase Efficacy ASCO of in arms the we that efficacy versus anticipate expansion will cancers endometrial announcing cancer top cohorts support the clinical cell and setting in update first-line a of three cancer. the in believe we in cohort medical cohort ovarian other further
turn me a now to Rubraca commercial Let update.
over detail. Our global period. Dan results revenue these down describe the XXXX greater for the in of XXXX comparable -- prior was quarter $XX.X will net first XX% million, year
time. adopter on is practices the access increasingly once their that pandemic will is digital us of of communication programming, that remaining we a increasingly the oncology meet We about a commercial under have early already peer-to-peer those preferred an control, And of our enable trend reps. more be We COVID-XX even to much was oncology COVID-XX interactions. preferences, for sales the targeted. additional virtual reduced marketers. strategy, In-person remain believe that of toward substantial to we lessen embraces be we reduced. reduced are programming trend This and what digital believe practices the acceleration these this as discussed strategy community-based As and that and own a academic will will effect continue, by ultimately We effects promotion believe fall clinics can overtime. strategy activities in-person previously, are an access accessed, last communication elevates is and to in-person as common energized introduced accessible approach easily hybrid
overtime. our that impact sales. QX experience growth QX, on ongoing share In have industry as resources, sales across virus COVID-related better hybrid our strategy, in in physicians way to to the their months. this appeared impact announced with believe customized be several maintained goal the adopted to changes we they similar reach companies utilizing our the recent of to we U.S. We the fact, to reached, practices resolves given U.S. Despite of market also the compared competitors lower accelerating want
hybrid cost-effective our we contributor commercial prostate model U.S. regard and model is proof of modest come customers While SG&A, we hope indication consistent will we with a COVID-XX, but sales was with specific in to sales while the share for potential the costs, this U.S. XX% the to to as reduction model, a also this environment XXXX. of more a model of prostate address maintained reduction physician not our U.S. in in Obviously, still selling out to accelerate our Rubraca difficult revenues QX indication, yet XXXX. we our QX Not of were in to we growth. found the have commercial our clearly a compared with a all believe in hybrid With
lockdowns remain of pleased very place countries. most first were our with progress Rubraca that to-date, quarter Europe, the compared to despite we in Turning up to in of XXXX. are significantly, COVID-XX the Sales
will As as oncology normal in believe practice that we Europe reemerge the U.S., reopens. a more
allow. and have Europe in organization commercial our smaller of each in been as a regulations have territories, We virtual communication utilizing primary
vary national European country compared among reach tailoring the we digital a U.S., clinician better prescribers. our to for each hybrid and While regulations are as countries strategy to
for December are to date, ANDA that the filed Orange not Rubraca been Rubraca. infringed, patents for had earliest asserting As or was been we entities that IV or XXth, an an that certification, could listed file At not Rubraca in with permitted explained Paragraph XXXX invalid either one have a the Book more time generic for enforceable. ANDA previously,
a XXXX. ANDA for notice with been with in, advanced a not I'm bioequivalence are of a initial cancer patients to have chemotherapies here, The two file associated additional of confidence Paragraph or mutation, and FDA including only Rubraca is treated camsylate. bioequivalence level. a forth, an a rucaparib would have filings listed also published certification sets criteria the receiving made challenger with process. who the recommend a We Demonstrating demonstration in the BRCA need our drug, camsylate step seeking cytotoxic Because female approval generic have and deleterious any any more be showing a XX% Book not generic regimen patents, of expire guidance rucaparib do to-date. for considered potential until design knowledge, of guidance IV a letters to ANDA around quoting which rucaparib litigation, to In no would form and bioequivalence received party rucaparib successfully with to some challenge or ANDA Orange approval bio-IND been requires
over me interest, call with moving growing Chief Now now briefly topics as development turn Tom? let to programs, FAP-XXXX. Officer FAP-XXXX the are Dr. nucleotide and targeted our discuss Scientific Thomas the to into of Harding, therapeutic we clinical
